The seed round was backed by Trucks Venture Capital, Luminous Ventures and Jaguar Land Rover.
"AI has huge implications for the way businesses operate, yet so much of the modelling is done in carefully controlled test environments. When deployed in real world situations, anomalies always occur, which disrupts lab-grown models and undermines companies’ efforts to revolutionise how they use autonomous systems effectively. By scaling edge AI, optimising the endpoints collecting the data, and making models more resilient, we are radically accelerating learning and, in doing so, giving our customers a competitive advantage in a crowded marketplace."
The seed round was led by UCL Technology Fund and IP Group to help fund memory device prototyping.
"Existing memory technologies, such as Flash, are reaching the limits of their capabilities – particularly in embedded systems such as those we need in IoT devices. Intrinsic’s memristor technology will transform next generation systems by combining high performance with ease of integration in digital CMOS. By basing our devices on silicon oxide, we ensure that they are as simple and as cheap to integrate with silicon-based electronics as it is possible to be."
Origin Capital has led a seed investment in CyTAL to support the growth of its ProtoCrawler software.
"“We’re delighted to receive an investment from Origin, and the process we have been through to get here has really helped us to validate our future plans and ambitions. We’ve listened carefully to what our customers and the market are telling us, and developed ProtoCrawler accordingly. We look forward to welcoming Origin onto the board and exploiting their insights to help us become a leading player in cyber security product assurance and testing software.”"
The seed round was led by XTX Ventures and Prostate Cancer Research to support regulatory approvals and clinical studies.
"We are tremendously excited about the potential of this system to enhance our ability to detect cancer accurately and early. We are now looking forward to working with hospitals and radiology and urology partners to prove the technology and bring it into clinical use. Covid-19 has created a serious backlog in cancer screening and Lucida Medical is well placed to help us clear this and improve the care that we offer further over the coming years."
The over-subscribed funding round was organised by West Hill Capital to support the deployment of Lilli's machine learning care platform.
"The timing for this new preventative approach to care and integration of our smart technology is crucial in meeting the needs of ageing population, this has only been exacerbated by COVID 19. The role of technology has a vital role to play in the future success of care delivery across the UK and globally."
